title: Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer.
abstract: OBJECTIVE
  To find out an effective prognostic factor for early stage non-small cell lung cancer (NSCLC), we examined the relationship of the degree of tenascin-C (TN-C) degradation in relapsed NSCLC tumors with the prognosis of the patients. The molecular mechanism of TN-C degradation was also evaluated.
  
  
  METHODS
  In 63 stage-1 NSCLC patients, TN-C protein was analyzed by Western blotting, and the activity of matrix metalloproteinase (MMP)-2 was examined by gelatin zymography in 23 stage-1 NSCLC patients.
  
  
  RESULTS
  Degradation of TN-C was detected in 12 of 63 patients. TN-C degradation was detected in 9 of 17 patients (52.9%) that showed local and distant cancer recurrences. In short, in 9 of 12 patients (75%) showing TN-C degradation, lung cancer recurrence was recognized. The actual frequency of free-from-recurrence at 4 years was 28.1% in patients with tumors showing TN-C degradation, and actual frequency of free-from-recurrence at 4 years and 10 years was 82.1% and 76.6% in patients without TN-C degradation (P < 0.001). In 23 stage-1 NSCLC patients, in tumors with or without degraded TN-C, the mean ratio of tumor:normal-tissue of activated MMP-2 was 3.5 +/- 0.4 or 1.54 +/- 0.4, respectively. Significantly increased activity of MMP-2 was recognized in tumors showing TN-C degradation (P < 0.001).
  
  
  CONCLUSIONS
  These results suggest that TN-C degradation is a reliable marker for recurrence potential of stage-1 NSCLC and that MMP-2 may be a protease breaking down TN-C in lung cancer.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Mie University School of Medicine, Tsu, Mie, Japan 514-8507.
authors.forename: Ming
authors.initials: M
authors.lastname: Cai
authors.forename: Koji
authors.initials: K
authors.lastname: Onoda
authors.forename: Motoshi
authors.initials: M
authors.lastname: Takao
authors.forename: Imanaka-Yoshida
authors.initials: IY
authors.lastname: Kyoko
authors.forename: Hideto
authors.initials: H
authors.lastname: Shimpo
authors.forename: Toshimichi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Isao
authors.initials: I
authors.lastname: Yada
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015153:Blotting, Western; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D005780:Gelatin / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D016019:Survival Analysis; D019063:Tenascin / Q000378:metabolism*
chemical_list: D019063:Tenascin; D005780:Gelatin; D020778:Matrix Metalloproteinase 2